Global Preventive Vaccines Market 2020 2026

Bonafide Trust 28-11-2020 187 Pages Figures : 84 Tables : 85
Region : Global Category : Lifescience Pharmaceutical

Request new version

Request for updated version of the report at the same price

Order Now

Report Description
Table of Contents
List of Figure Tables

Global preventive vaccines market will reach $80.47 billion by 2026, growing by 10.81% annually over 2020-2026 owing to increasing healthcare expenditure, new development of the vaccines, and rising need for preventive vaccines especially new COVID-19 vaccines. Highlighted with 85 tables and 84 figures, this 187-page report “Global Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Region: COVID-19 Impact and Growth Opportunity” is based on a holistic research of the entire global preventive vaccines market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2016-2019 and provides forecast from 2020 till 2026 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global preventive vaccines market in every aspect of the classification from perspectives of Vaccine Type, Disease, Administration, Patient, and Region. Based on Vaccine Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Live/Attenuated Vaccines • Inactivated Vaccines • Subunit Vaccines • Toxoid Vaccines • Conjugate Vaccines • Recombinant Vector Vaccines • Other Vaccines Based on Disease, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Vaccines for Pneumococcal Disease • Vaccines for Poliovirus • Vaccines for Hepatitis • Vaccines for Influenza • Vaccines for Measles, Mumps, and Rubella (MMR) • Vaccines for Varicella • Vaccines for Human Papilloma Virus • Vaccines for COVID-19 • Vaccines for Other Diseases Based on Administration, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. • Intramuscular Route • Subcutaneous Route • Oral Route • Intravenous Injection • Other Administration Routes Based on Patient, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2016-2026 included in each section. Pediatric Vaccines • Pneumococcal • Measles, Mumps, and Rubella (MMR) • Varicella • Hepatitis • Poliovirus • Haemophilus Influenzae B (HIB) • Other Diseases Adult Vaccines • Influenza • Cervical Cancer • Hepatitis • Zoster • Other Diseases Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Columbia, Argentina, Rest of South America) • MEA (Saudi Arabia, UAE, Egypt) For each region and key country, detailed analysis and data for annual revenue ($ mn) are available for 2016-2026. The breakdown of all regional markets by country and split of key national markets by Vaccine Type, Disease, and Route of Administration over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global preventive vaccines market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca plc Bavarian Nordic A/S China National Biotec Group Company Ltd. CSL Ltd. Daiichi Sankyo Co. Ltd Emergent BioSolutions Inc. GlaxoSmithKline PLC Johnson & Johnson Merck & Co. Novavax, Inc. Pfizer Inc. Sanofi SA Takeda Pharmaceutical Co. Ltd (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

1 Introduction 8

1.1 Industry Definition and Research Scope 8

1.1.1 Industry Definition 8

1.1.2 Research Scope 9

1.2 Research Methodology 12

1.2.1 Overview of Market Research Methodology 12

1.2.2 Market Assumption 13

1.2.3 Secondary Data 13

1.2.4 Primary Data 13

1.2.5 Data Filtration and Model Design 15

1.2.6 Market Size/Share Estimation 16

1.2.7 Research Limitations 17

1.3 Executive Summary 18

2 Market Overview and Dynamics 21

2.1 Market Size and Forecast 21

2.1.1 Impact of COVID-19 on World Economy 23

2.1.2 Impact of COVID-19 on the Market 26

2.2 Major Growth Drivers 28

2.3 Market Restraints and Challenges 31

2.4 Emerging Opportunities and Market Trends 34

2.5 Porter’s Fiver Forces Analysis 38

3 Segmentation of Global Market by Vaccine Type 42

3.1 Market Overview by Vaccine Type 42

3.2 Live/Attenuated Vaccines 44

3.3 Inactivated Vaccines 45

3.4 Subunit Vaccines 46

3.5 Toxoid Vaccines 47

3.6 Conjugate Vaccines 48

3.7 Recombinant Vector Vaccines 49

3.8 Other Vaccines 50

4 Segmentation of Global Market by Disease 51

4.1 Market Overview by Disease 51

4.2 Vaccines for Pneumococcal Disease 53

4.3 Vaccines for Poliovirus 54

4.4 Vaccines for Hepatitis 55

4.5 Vaccines for Influenza 56

4.6 Vaccines for Measles, Mumps, and Rubella (MMR) 57

4.7 Vaccines for Varicella 58

4.8 Vaccines for Human Papilloma Virus 59

4.9 Vaccines for COVID-19 60

4.10 Vaccines for Other Diseases 61

5 Segmentation of Global Market by Administration 62

5.1 Market Overview by Administration 62

5.2 Intramuscular Route 64

5.3 Subcutaneous Route 65

5.4 Oral Route 66

5.5 Intravenous Injection 67

5.6 Other Administration Routes 68

6 Segmentation of Global Market by Patient 69

6.1 Market Overview by Patient 69

6.2 Pediatric Vaccines 71

6.3 Adult Vaccines 73

7 Segmentation of Global Market by Region 75

7.1 Geographic Market Overview 2019-2026 75

7.2 North America Market 2019-2026 by Country 79

7.2.1 Overview of North America Market 79

7.2.2 U.S. 82

7.2.3 Canada 87

7.2.4 Mexico 90

7.3 European Market 2019-2026 by Country 93

7.3.1 Overview of European Market 93

7.3.2 UK 96

7.3.3 France 99

7.3.4 Germany 102

7.3.5 Spain 105

7.3.6 Italy 108

7.3.7 Russia 111

7.3.8 Rest of European Market 114

7.4 Asia-Pacific Market 2019-2026 by Country 116

7.4.1 Overview of Asia-Pacific Market 116

7.4.2 China 119

7.4.3 Japan 122

7.4.4 India 126

7.4.5 Australia 129

7.4.6 South Korea 132

7.4.7 Rest of APAC Region 135

7.5 South America Market 2019-2026 by Country 137

7.5.1 Argentina 140

7.5.2 Brazil 143

7.5.3 Columbia 146

7.5.4 Rest of South America Market 149

7.6 MEA Market 2019-2026 by Country 150

7.6.1 UAE 153

7.6.2 Saudi Arabia 156

7.6.3 Egypt 159

7.6.4 Other National Markets 162

8 Competitive Landscape 163

8.1 Overview of Key Vendors 163

8.2 New Product Launch, Partnership, Investment, and M&A 166

8.3 Company Profiles 167

AstraZeneca plc 167

Bavarian Nordic A/S 169

China National Biotec Group Company Ltd. 170

CSL Ltd. 171

Daiichi Sankyo Co. Ltd 172

Emergent BioSolutions Inc. 173

GlaxoSmithKline PLC 174

Johnson & Johnson 175

Merck & Co. 176

Novavax, Inc. 177

Pfizer Inc. 178

Sanofi SA 179

Takeda Pharmaceutical Co. Ltd 180

9 Investing in Global Market: Risk Assessment and Management 181

9.1 Risk Evaluation of Global Market 181

9.2 Critical Success Factors (CSFs) 184

Related Reports and Products 187

Figure 1. Research Method Flow Chart 12
Figure 2. Breakdown of Primary Research 14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2026 18
Figure 5. Global Preventive Vaccines Market, 2019-2026, $ mn 21
Figure 6. Development Stages of Preventive Vaccines 22
Figure 7. Impact of COVID-19 on Business 26
Figure 8. Primary Drivers and Impact Factors of Global Preventive Vaccines Market 28
Figure 9. Primary Restraints and Impact Factors of Global Preventive Vaccines Market 31
Figure 10. Investment Opportunity Analysis 35
Figure 11. Porter’s Fiver Forces Analysis of Global Preventive Vaccines Market 38
Figure 12. Breakdown of Global Preventive Vaccines Market by Vaccine Type, 2019-2026, % of Revenue 43
Figure 13. Contribution to Global 2020-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%) 43
Figure 14. Global Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn 44
Figure 15. Global Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn 45
Figure 16. Global Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn 46
Figure 17. Global Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn 47
Figure 18. Global Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn 48
Figure 19. Global Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn 49
Figure 20. Global Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn 50
Figure 21. Breakdown of Global Preventive Vaccines Market by Disease, 2019-2026, % of Revenue 52
Figure 22. Contribution to Global 2020-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%) 52
Figure 23. Global Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn 53
Figure 24. Global Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn 54
Figure 25. Global Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn 55
Figure 26. Global Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn 56
Figure 27. Global Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn 57
Figure 28. Global Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn 58
Figure 29. Global Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn 59
Figure 30. Global Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn 60
Figure 31. Global Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn 61
Figure 32. Breakdown of Global Preventive Vaccines Market by Administration, 2019-2026, % of Revenue 63
Figure 33. Contribution to Global 2020-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%) 63
Figure 34. Global Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn 64
Figure 35. Global Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn 65
Figure 36. Global Preventive Vaccines Market: Oral Route, 2016-2026, $ mn 66
Figure 37. Global Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn 67
Figure 38. Global Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn 68
Figure 39. Breakdown of Global Preventive Vaccines Market by Patient, 2019-2026, % of Revenue 69
Figure 40. Contribution to Global 2020-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%) 70
Figure 41. Global Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn 71
Figure 42. Global Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn 73
Figure 43. Global Market Snapshot by Region 75
Figure 44. Geographic Spread of Worldwide Preventive Vaccines Market, 2019-2026, % of Revenue 76
Figure 45. Contribution to Global 2020-2026 Cumulative Revenue by Region, Value ($ mn) and Share (%) 77
Figure 46. North American Preventive Vaccines Market, 2016-2026, $ mn 80
Figure 47. Breakdown of North America Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 80
Figure 48. Contribution to North America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 81
Figure 49. U.S. Preventive Vaccines Market, 2016-2026, $ mn 83
Figure 50. Canada Preventive Vaccines Market, 2016-2026, $ mn 87
Figure 51. Preventive Vaccines Market in Mexico, 2016-2026, $ mn 90
Figure 52. European Preventive Vaccines Market, 2016-2026, $ mn 94
Figure 53. Breakdown of European Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 94
Figure 54. Contribution to Europe 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 95
Figure 55. Preventive Vaccines Market in UK, 2016-2026, $ mn 96
Figure 56. Preventive Vaccines Market in France, 2016-2026, $ mn 99
Figure 57. Preventive Vaccines Market in Germany, 2016-2026, $ mn 102
Figure 58. Preventive Vaccines Market in Spain, 2016-2026, $ mn 105
Figure 59. Preventive Vaccines Market in Italy, 2016-2026, $ mn 108
Figure 60. Preventive Vaccines Market in Russia, 2016-2026, $ mn 111
Figure 61. Preventive Vaccines Market in Rest of Europe, 2016-2026, $ mn 114
Figure 62. Asia-Pacific Preventive Vaccines Market, 2016-2026, $ mn 117
Figure 63. Breakdown of APAC Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 117
Figure 64. Contribution to APAC 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 118
Figure 65. Preventive Vaccines Market in China, 2016-2026, $ mn 119
Figure 66. Preventive Vaccines Market in Japan, 2016-2026, $ mn 123
Figure 67. Preventive Vaccines Market in India, 2016-2026, $ mn 126
Figure 68. Preventive Vaccines Market in Australia, 2016-2026, $ mn 129
Figure 69. Preventive Vaccines Market in South Korea, 2016-2026, $ mn 132
Figure 70. Preventive Vaccines Market in Rest of APAC, 2016-2026, $ mn 135
Figure 71. South America Preventive Vaccines Market, 2016-2026, $ mn 138
Figure 72. Breakdown of South America Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 138
Figure 73. Contribution to South America 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 139
Figure 74. Preventive Vaccines Market in Argentina, 2016-2026, $ mn 140
Figure 75. Preventive Vaccines Market in Brazil, 2016-2026, $ mn 143
Figure 76. Preventive Vaccines Market in Columbia, 2016-2026, $ mn 146
Figure 77. Preventive Vaccines Market in Rest of South America, 2016-2026, $ mn 149
Figure 78. Preventive Vaccines Market in Middle East and Africa (MEA), 2016-2026, $ mn 151
Figure 79. Breakdown of MEA Preventive Vaccines Market by Country, 2019 and 2026, % of Revenue 151
Figure 80. Contribution to MEA 2020-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%) 152
Figure 81. Preventive Vaccines Market in UAE, 2016-2026, $ mn 153
Figure 82. Preventive Vaccines Market in Saudi Arabia, 2016-2026, $ mn 156
Figure 83. Preventive Vaccines Market in Egypt, 2016-2026, $ mn 159
Figure 84. Growth Stage of Global Preventive Vaccines Industry over the Forecast Period 163

Table 1. Snapshot of Global Preventive Vaccines Market in Balanced Perspective, 2019-2026 19
Table 2. Growth Rate of World Real GDP, 2017-2021 24
Table 3. Main Product Trends and Market Opportunities in Global Preventive Vaccines Market 34
Table 4. Global Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 42
Table 5. Global Preventive Vaccines Market by Disease, 2016-2026, $ mn 51
Table 6. Global Preventive Vaccines Market by Administration, 2016-2026, $ mn 62
Table 7. Global Preventive Vaccines Market by Patient, 2016-2026, $ mn 69
Table 8. Global Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn 72
Table 9. Global Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn 74
Table 10. Global Preventive Vaccines Market by Region, 2016-2026, $ mn 76
Table 11. Leading National Preventive Vaccines Market, 2019 and 2026, $ mn 78
Table 12. North America Preventive Vaccines Market by Country, 2016-2026, $ mn 81
Table 13. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 84
Table 14. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn 84
Table 15. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn 85
Table 16. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 88
Table 17. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn 88
Table 18. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn 89
Table 19. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 91
Table 20. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 91
Table 21. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 92
Table 22. Europe Preventive Vaccines Market by Country, 2016-2026, $ mn 95
Table 23. UK Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 97
Table 24. UK Preventive Vaccines Market by Disease, 2016-2026, $ mn 97
Table 25. UK Preventive Vaccines Market by Administration, 2016-2026, $ mn 98
Table 26. France Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 100
Table 27. France Preventive Vaccines Market by Disease, 2016-2026, $ mn 100
Table 28. France Preventive Vaccines Market by Administration, 2016-2026, $ mn 101
Table 29. Germany Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 103
Table 30. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 103
Table 31. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 104
Table 32. Spain Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 106
Table 33. Spain Preventive Vaccines Market by Disease, 2016-2026, $ mn 106
Table 34. Spain Preventive Vaccines Market by Administration, 2016-2026, $ mn 107
Table 35. Italy Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 109
Table 36. Italy Preventive Vaccines Market by Disease, 2016-2026, $ mn 109
Table 37. Italy Preventive Vaccines Market by Administration, 2016-2026, $ mn 110
Table 38. Russia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 112
Table 39. Germany Preventive Vaccines Market by Disease, 2016-2026, $ mn 112
Table 40. Germany Preventive Vaccines Market by Administration, 2016-2026, $ mn 113
Table 41. Preventive Vaccines Market in Rest of Europe by Country, 2016-2026, $ mn 115
Table 42. APAC Preventive Vaccines Market by Country, 2016-2026, $ mn 118
Table 43. China Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 120
Table 44. China Preventive Vaccines Market by Disease, 2016-2026, $ mn 120
Table 45. China Preventive Vaccines Market by Administration, 2016-2026, $ mn 121
Table 46. Japan Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 124
Table 47. Japan Preventive Vaccines Market by Disease, 2016-2026, $ mn 124
Table 48. Japan Preventive Vaccines Market by Administration, 2016-2026, $ mn 125
Table 49. India Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 127
Table 50. India Preventive Vaccines Market by Disease, 2016-2026, $ mn 127
Table 51. India Preventive Vaccines Market by C Administration, 2016-2026, $ mn 128
Table 52. Australia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 130
Table 53. Australia Preventive Vaccines Market by Disease, 2016-2026, $ mn 130
Table 54. Australia Preventive Vaccines Market by Administration, 2016-2026, $ mn 131
Table 55. South Korea Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 133
Table 56. South Korea Preventive Vaccines Market by Disease, 2016-2026, $ mn 133
Table 57. South Korea Preventive Vaccines Market by Administration, 2016-2026, $ mn 134
Table 58. Preventive Vaccines Market in Rest of APAC by Country, 2016-2026, $ mn 136
Table 59. South America Preventive Vaccines Market by Country, 2016-2026, $ mn 139
Table 60. Argentina Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 141
Table 61. Argentina Preventive Vaccines Market by Disease, 2016-2026, $ mn 141
Table 62. Argentina Preventive Vaccines Market by Administration, 2016-2026, $ mn 142
Table 63. Brazil Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 144
Table 64. Brazil Preventive Vaccines Market by Disease, 2016-2026, $ mn 144
Table 65. Brazil Preventive Vaccines Market by Administration, 2016-2026, $ mn 145
Table 66. Columbia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 147
Table 67. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn 147
Table 68. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn 148
Table 69. MEA Preventive Vaccines Market by Country, 2016-2026, $ mn 152
Table 70. UAE Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 154
Table 71. UAE Preventive Vaccines Market by Disease, 2016-2026, $ mn 154
Table 72. UAE Preventive Vaccines Market by Administration, 2016-2026, $ mn 155
Table 73. Saudi Arabia Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 157
Table 74. Saudi Arabia Preventive Vaccines Market by Disease, 2016-2026, $ mn 157
Table 75. Saudi Arabia Preventive Vaccines Market by Administration, 2016-2026, $ mn 158
Table 76. Egypt Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn 160
Table 77. Egypt Preventive Vaccines Market by Disease, 2016-2026, $ mn 160
Table 78. Egypt Preventive Vaccines Market by Administration, 2016-2026, $ mn 161
Table 79. AstraZeneca plc: Company Snapshot 167
Table 80. AstraZeneca plc: Business Segmentation 167
Table 81. AstraZeneca plc: Product Portfolio 168
Table 82. AstraZeneca plc: Revenue, 2016-2018, $ mn 168
Table 83. AstraZeneca plc: Recent Developments 168
Table 84. Risk Evaluation for Investing in Global Market, 2019-2026 182
Table 85. Critical Success Factors and Key Takeaways 185

Interested in this report?
Get your FREE sample!

Safe and Secure SSl Encryption

Licensing options

3200
USD

Single User License
Site License
Global User License

How client has rates us?

Requirement Gathering & Methodology

Data Collection Techniques

Our Research Team & Data Sourcing

Data Science & Analytical Tools

Data Visualization & Presentation Skills

Project/ Report Delivery & After Sales Services

Testimonial

READY TO MIX MARKET HAS HELPED US TO UNDERSTAND PRODUCT, PRICE & VARIENTS OF ALL THE COMPETITION INCLUDING SMALL STARTUPS/REGIONAL PLAYERS.

PRODUCT DEVELOPMENT MANAGER

CEO

Vivek Arora

BEING A STARTUP WE WERE NOT AWARE ABOUT E-COMMERCE LOGISTICS, THE REPORT HAS RESOLVED ALL OUR QUERIES. THE TEAM HAVE IN DEPTH KNOWLEDGE OF LOGISTICS. REMARKABLE!!

EXECUTIVE DIRECTOR

Rahul Roy

THE REPORT WAS GOOD FOR OUR STUDY, I WOULD STRONGLY RECOMMEND BONAFIDE RESEARCH. A VERY CUSTOMER CENTRIC AND APPROACHABLE TEAM.

SALES DIRECTOR

Arjun Prasad

THE COMPANY WHICH THOROUGHLY UNDERSTANDS INDIAN CONSUMER AND INDIAN MARKET. WE ARE REALLY HAPPY TO WORK WITH BONAFIDE RESEARCH

MARKETING MANAGER

President

Manish Verma

Bonafide Research did an outstanding work on Global Hand Sanitizer project. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

MARKETING DIRECTOR

Gautam Saxena

The study done by Bonafide Research was customized with all our needs. We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done.

PRODUCT MANAGER

Tom Stone

I’m glad I decided to work with you. Thankful to the team for the amazing coordination, it was indeed a good experience, would definitely recommend and come back for future prospects.

Associate Director

Mark Wood

Global Preventive Vaccines Market 2020 2026

Global Preventive Vaccines Market 2020 2026